LLY

986.56

-0.73%↓

JNJ

203.98

+0.93%↑

ABBV

222.31

-0.22%↓

UNH

324.5

+0.36%↑

AZN

90.06

+0.1%↑

LLY

986.56

-0.73%↓

JNJ

203.98

+0.93%↑

ABBV

222.31

-0.22%↓

UNH

324.5

+0.36%↑

AZN

90.06

+0.1%↑

LLY

986.56

-0.73%↓

JNJ

203.98

+0.93%↑

ABBV

222.31

-0.22%↓

UNH

324.5

+0.36%↑

AZN

90.06

+0.1%↑

LLY

986.56

-0.73%↓

JNJ

203.98

+0.93%↑

ABBV

222.31

-0.22%↓

UNH

324.5

+0.36%↑

AZN

90.06

+0.1%↑

LLY

986.56

-0.73%↓

JNJ

203.98

+0.93%↑

ABBV

222.31

-0.22%↓

UNH

324.5

+0.36%↑

AZN

90.06

+0.1%↑

Inicio・Lista de Acciones・Prothena Corp PLC

Prothena Corp PLC

Abierto

SectorSanidad

9.77 -7.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.71

Máximo

10.59

Métricas clave
By Trading Economics
Ingresos	89M -37M
Ventas	-2M 2.4M
Margen de beneficios	-1,513.085
Empleados	163
EBITDA	16M -36M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+93.85% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	10M 578M
Apertura anterior	17.43
Cierre anterior	9.77

Noticias sobre sentimiento de mercado

By Acuity

42%

58%

156 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

N/A / 7.35 Soporte y Resistencia

Prothena Corp PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 dic 2025, 22:13 UTC

Ganancias

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Ganancias

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

Principales Movimientos del Mercado

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Ganancias

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Charlas de Mercado

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Charlas de Mercado

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Charlas de Mercado

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Ganancias

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Ganancias

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Ganancias

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Prothena Corp PLC previsión

Precio Objetivo

By TipRanks

93.85% repunte

Estimación a 12 Meses

Media 20.8 USD 93.85%

Máximo 36 USD

Mínimo 8 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Prothena Corp PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Prothena Corp PLC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 7.35Soporte y Resistencia

All events are bearish.

Sentimiento

By Acuity

156 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.